BerGenBio ASA Information

On 29 October 2025, BerGenBio ASA completed its merger with Oncoinvent ASA. The combined company now operates under the name Oncoinvent ASA. Oncoinvent ASA is alone in developing cancer treatment using alpha radiation for patients with cancer in the abdominal cavity – a condition with very few treatment options and a high rate of recurrence. Preliminary studies show positive research findings. The company has begun recruitment for phase 2 studies, both in Norway and internationally. For more information about the new company, please visit Oncoinvent ASA: https://www.linkedin.com/company/oncoinvent-as/ BerGenBio’s LinkedIn page will be maintained as a historical archive. BerGenBio was a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.